JP2006520611A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2006520611A5 JP2006520611A5 JP2006509126A JP2006509126A JP2006520611A5 JP 2006520611 A5 JP2006520611 A5 JP 2006520611A5 JP 2006509126 A JP2006509126 A JP 2006509126A JP 2006509126 A JP2006509126 A JP 2006509126A JP 2006520611 A5 JP2006520611 A5 JP 2006520611A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- seq
- expression
- apoptosis
- composition according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108020004459 Small interfering RNA Proteins 0.000 claims description 15
- 230000006907 apoptotic process Effects 0.000 claims description 14
- 230000000692 anti-sense effect Effects 0.000 claims description 12
- 239000002773 nucleotide Substances 0.000 claims description 10
- 125000003729 nucleotide group Chemical group 0.000 claims description 10
- 230000000295 complement effect Effects 0.000 claims description 9
- 239000003795 chemical substances by application Substances 0.000 claims description 8
- 108010074105 Factor Va Proteins 0.000 claims description 4
- 108091033319 polynucleotide Proteins 0.000 claims description 3
- 239000002157 polynucleotide Substances 0.000 claims description 3
- 102000040430 polynucleotide Human genes 0.000 claims description 3
- 239000008194 pharmaceutical composition Substances 0.000 claims 44
- 108091034117 Oligonucleotide Proteins 0.000 claims 15
- 239000000074 antisense oligonucleotide Substances 0.000 claims 11
- 238000012230 antisense oligonucleotides Methods 0.000 claims 11
- 102000016614 Autophagy-Related Protein 5 Human genes 0.000 claims 8
- 108010092776 Autophagy-Related Protein 5 Proteins 0.000 claims 8
- 210000004027 cell Anatomy 0.000 claims 7
- 102000004127 Cytokines Human genes 0.000 claims 6
- 108090000695 Cytokines Proteins 0.000 claims 6
- 239000003814 drug Substances 0.000 claims 5
- 229940079593 drug Drugs 0.000 claims 5
- GOZMBJCYMQQACI-UHFFFAOYSA-N 6,7-dimethyl-3-[[methyl-[2-[methyl-[[1-[3-(trifluoromethyl)phenyl]indol-3-yl]methyl]amino]ethyl]amino]methyl]chromen-4-one;dihydrochloride Chemical compound Cl.Cl.C=1OC2=CC(C)=C(C)C=C2C(=O)C=1CN(C)CCN(C)CC(C1=CC=CC=C11)=CN1C1=CC=CC(C(F)(F)F)=C1 GOZMBJCYMQQACI-UHFFFAOYSA-N 0.000 claims 3
- 102100025064 Cellular tumor antigen p53 Human genes 0.000 claims 3
- 101000721661 Homo sapiens Cellular tumor antigen p53 Proteins 0.000 claims 3
- 210000001130 astrocyte Anatomy 0.000 claims 3
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 claims 2
- 108010002352 Interleukin-1 Proteins 0.000 claims 2
- 108090001005 Interleukin-6 Proteins 0.000 claims 2
- 108060008682 Tumor Necrosis Factor Proteins 0.000 claims 2
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 claims 2
- 230000004069 differentiation Effects 0.000 claims 2
- 230000002401 inhibitory effect Effects 0.000 claims 2
- 210000001616 monocyte Anatomy 0.000 claims 2
- 210000000056 organ Anatomy 0.000 claims 2
- 210000003994 retinal ganglion cell Anatomy 0.000 claims 2
- 230000008685 targeting Effects 0.000 claims 2
- 108020000948 Antisense Oligonucleotides Proteins 0.000 claims 1
- 102100021569 Apoptosis regulator Bcl-2 Human genes 0.000 claims 1
- 208000023328 Basedow disease Diseases 0.000 claims 1
- 206010009900 Colitis ulcerative Diseases 0.000 claims 1
- 208000011231 Crohn disease Diseases 0.000 claims 1
- 201000003883 Cystic fibrosis Diseases 0.000 claims 1
- 201000004624 Dermatitis Diseases 0.000 claims 1
- 208000010412 Glaucoma Diseases 0.000 claims 1
- 208000015023 Graves' disease Diseases 0.000 claims 1
- 101000971171 Homo sapiens Apoptosis regulator Bcl-2 Proteins 0.000 claims 1
- 206010020751 Hypersensitivity Diseases 0.000 claims 1
- 108090000171 Interleukin-18 Proteins 0.000 claims 1
- 201000002287 Keratoconus Diseases 0.000 claims 1
- 208000034578 Multiple myelomas Diseases 0.000 claims 1
- 208000023715 Ocular surface disease Diseases 0.000 claims 1
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 1
- 201000004681 Psoriasis Diseases 0.000 claims 1
- 206010063837 Reperfusion injury Diseases 0.000 claims 1
- 206010040047 Sepsis Diseases 0.000 claims 1
- 206010052779 Transplant rejections Diseases 0.000 claims 1
- 201000006704 Ulcerative Colitis Diseases 0.000 claims 1
- 208000026935 allergic disease Diseases 0.000 claims 1
- 230000007815 allergy Effects 0.000 claims 1
- 206010003230 arteritis Diseases 0.000 claims 1
- 208000006673 asthma Diseases 0.000 claims 1
- 208000010668 atopic eczema Diseases 0.000 claims 1
- 230000030833 cell death Effects 0.000 claims 1
- 208000029078 coronary artery disease Diseases 0.000 claims 1
- 206010012601 diabetes mellitus Diseases 0.000 claims 1
- 210000002919 epithelial cell Anatomy 0.000 claims 1
- 210000005260 human cell Anatomy 0.000 claims 1
- 208000028867 ischemia Diseases 0.000 claims 1
- 210000003734 kidney Anatomy 0.000 claims 1
- 206010025135 lupus erythematosus Diseases 0.000 claims 1
- 208000002780 macular degeneration Diseases 0.000 claims 1
- 201000006417 multiple sclerosis Diseases 0.000 claims 1
- 201000008482 osteoarthritis Diseases 0.000 claims 1
- 230000001575 pathological effect Effects 0.000 claims 1
- 208000028169 periodontal disease Diseases 0.000 claims 1
- 230000000770 proinflammatory effect Effects 0.000 claims 1
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US45167703P | 2003-03-05 | 2003-03-05 | |
| US10/383,614 US7381708B2 (en) | 2001-07-23 | 2003-03-10 | Suppression of eIF5A1 expression by the use of antisense oligonucleotides for the prevention of retinal cell death in the glaucomatous eye |
| US47619403P | 2003-06-06 | 2003-06-06 | |
| US50473103P | 2003-09-22 | 2003-09-22 | |
| PCT/US2004/006598 WO2004078940A2 (en) | 2003-03-05 | 2004-03-05 | USE OF ANTISENSE OLIGONUCLEOTIDES OR siRNA TO SUPPRESS EXPRESSION OF eIF-5A1 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010229103A Division JP5566250B2 (ja) | 2003-03-05 | 2010-10-08 | ｅＩＦ−５Ａ１の発現を抑制するための、アンチセンス・オリゴヌクレオチド又はｓｉＲＮＡの使用 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2006520611A JP2006520611A (ja) | 2006-09-14 |
| JP2006520611A5 true JP2006520611A5 (enExample) | 2007-05-31 |
Family
ID=32966688
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006509126A Pending JP2006520611A (ja) | 2003-03-05 | 2004-03-05 | ｅＩＦ−５Ａ１の発現を抑制するための、アンチセンス・オリゴヌクレオチド又はｓｉＲＮＡの使用 |
Country Status (9)
| Country | Link |
|---|---|
| US (5) | US20100168047A9 (enExample) |
| EP (1) | EP1601767B1 (enExample) |
| JP (1) | JP2006520611A (enExample) |
| KR (1) | KR20050098954A (enExample) |
| AU (1) | AU2004217437B2 (enExample) |
| CA (1) | CA2517974A1 (enExample) |
| NZ (1) | NZ542665A (enExample) |
| TW (1) | TW200427695A (enExample) |
| WO (1) | WO2004078940A2 (enExample) |
Families Citing this family (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7381708B2 (en) | 2001-07-23 | 2008-06-03 | Sensco Technologies, Inc. | Suppression of eIF5A1 expression by the use of antisense oligonucleotides for the prevention of retinal cell death in the glaucomatous eye |
| NZ542665A (en) * | 2003-03-05 | 2008-05-30 | Senesco Technologies Inc | Use of antisense oligonucleotides or siRNA to suppress expression of eIF-5A1 |
| CN101014708B (zh) * | 2003-03-05 | 2011-11-02 | 森尼斯科技术公司 | 反义寡核苷酸或siRNA在抑制eIF-5A1表达中的应用 |
| NZ574973A (en) * | 2003-06-06 | 2010-10-29 | Senesco Technologies Inc | Inhibition of apoptosis-specific eIF-5A ("eIF-5A1") with antisense oligonucleotides and siRNAs as anti-inflammatory therapeutics |
| US20140371299A1 (en) * | 2004-06-07 | 2014-12-18 | Senesco Technologies, Inc. | Use of Apoptosis-Specific elF-5A siRNA to Down Regulate Expression of Proinflammatory Cytokines to Treat Sepsis |
| TW200615001A (en) * | 2004-07-20 | 2006-05-16 | Senesco Technologies Inc | Use of apoptosis-specific eIF-5A siRNAs and antisense polynucleotides to inhibit/suppress an inflammatory response |
| WO2006060823A2 (en) * | 2004-12-03 | 2006-06-08 | Senesco Technologies, Inc. | Apoptosis-specific eif-5a and polynucleotides encoding same |
| NZ587138A (en) * | 2004-12-03 | 2012-06-29 | Senesco Technologies Inc | Methods of increasing seed yield |
| KR20080009048A (ko) | 2005-01-25 | 2008-01-24 | 프롤렉시스 파마슈티칼스, 인크. | 항종양제로서 퀴녹살린 유도체 |
| DE102005005528A1 (de) * | 2005-01-30 | 2006-08-03 | Eberhard-Karls-Universität Tübingen Universitätsklinikum | Injizierbares Mittel zur zielgerichteten Behandlung von retinalen Ganglienzellen |
| US8105611B2 (en) * | 2005-06-17 | 2012-01-31 | Allergan, Inc. | Treatment of autoimmune disorder with a neurotoxin |
| TWI441651B (zh) * | 2005-12-13 | 2014-06-21 | Senesco Technologies Inc | ｅＩＦ-５Ａ於殺多發性骨髓瘤細胞之用途 |
| KR20080070879A (ko) * | 2006-03-20 | 2008-07-31 | 세네스코 테크놀로지스 인코포레이티드 | 패혈증 또는 출혈성 쇼크를 치료하기 위한 ｅＩＦ-5Ａ1ｓｉＲＮＡ 및 안티센스의 용도 |
| EP1996707A2 (en) * | 2006-03-20 | 2008-12-03 | Senesco Technologies, Inc. | A novel method of protecting islet cells from apoptosis during the donor harvesting process |
| WO2007115047A2 (en) * | 2006-03-29 | 2007-10-11 | Senesco Technologies, Inc. | Inhibition of hiv replication and expression of p24 with eif-5a |
| WO2008053487A2 (en) | 2006-11-01 | 2008-05-08 | The Medical Research Fund At The Tel-Aviv Sourasky Medical Center | Adipocyte-specific constructs and methods for inhibiting platelet-type 12 lipoxygenase expression |
| WO2008065429A1 (en) * | 2006-11-30 | 2008-06-05 | Ucl Business Plc | Method for delivering gene therapy vectors to the optic nerve head |
| CN101126098B (zh) * | 2007-07-05 | 2012-07-11 | 深圳市第二人民医院 | 特异性抑制gfap蛋白表达的小干扰rna分子表达载体及其构建方法与用途 |
| AU2009223615B2 (en) | 2008-03-07 | 2014-09-11 | Senesco Technologies, Inc. | Use of siRNA to achieve down regulation of an endogenous gene in combination with the use of a sense construct to achieve expression of a desired polynucleotide |
| WO2009144933A1 (ja) | 2008-05-27 | 2009-12-03 | 国立大学法人東京大学 | アポトーシス誘導薬 |
| US8946239B2 (en) | 2008-07-10 | 2015-02-03 | Duquesne University Of The Holy Spirit | Substituted pyrrolo, -furano, and cyclopentylpyrimidines having antimitotic and/or antitumor activity and methods of use thereof |
| US8445638B2 (en) | 2008-09-03 | 2013-05-21 | Senesco Technologies, Inc. | Use of a truncated eIF-5A1 polynucleotide to induce apoptosis in cancer cells |
| KR101672563B1 (ko) | 2008-10-22 | 2016-11-03 | 쿠아크 파마수티칼스 인코퍼레이티드 | 안질환을 치료하는 방법 |
| US20120196918A1 (en) * | 2009-04-08 | 2012-08-02 | Mirmira Raghavendra G | PREVENTING ISLET INFLAMMATION AND DYSFUNCTION AND MAINTAINING PROPER GLUCOSE LEVELS BY CONTROLLING eIF5A AND ITS HYPUSINATION |
| CA2782676C (en) | 2009-12-01 | 2021-06-15 | Shire Human Genetic Therapies, Inc. | Pharmaceutical compositions for intracellular delivery of nucleic acids and proteins and uses thereof for treatment of ureca cycle metabolic disorders |
| CA3107288A1 (en) | 2011-06-08 | 2012-12-13 | Translate Bio, Inc. | Lipid nanoparticle compositions and methods for mrna delivery |
| EP2859102A4 (en) * | 2012-06-08 | 2016-05-11 | Shire Human Genetic Therapies | NUCLEASE RESISTANT POLYNUCLEOTIDES AND USES THEREOF |
| MX365409B (es) | 2013-03-14 | 2019-05-31 | Shire Human Genetic Therapies | Composiciones de ácido ribonucleico mensajero del regulador transmembrana de fibrosis quística y métodos y usos relacionados. |
| EA201591229A1 (ru) | 2013-03-14 | 2016-01-29 | Шир Хьюман Дженетик Терапис, Инк. | Способы очистки матричной рнк |
| CA2909442A1 (en) | 2013-04-17 | 2014-10-23 | Pfizer Inc. | N-piperidin-3-ylbenzamide derivatives for treating cardiovascular diseases |
| CN103421791B (zh) * | 2013-06-24 | 2015-04-15 | 广西医科大学 | 一种抑制人-单核巨噬细胞TLR2表达的siRNA及其应用 |
| MX2016005239A (es) | 2013-10-22 | 2016-08-12 | Shire Human Genetic Therapies | Tratamiento con acido ribonucleico mensajero para la fenilcetonuria. |
| EP3060303B1 (en) | 2013-10-22 | 2018-11-14 | Translate Bio, Inc. | Mrna therapy for argininosuccinate synthetase deficiency |
| KR20250005450A (ko) | 2014-04-25 | 2025-01-09 | 샤이어 휴먼 지네틱 테라피즈 인크. | 메신저 rna 의 정제 방법 |
| EA201991747A1 (ru) | 2017-02-27 | 2020-06-04 | Транслейт Био, Инк. | НОВАЯ КОДОН-ОПТИМИЗИРОВАННАЯ мРНК CFTR |
| CA3063531A1 (en) | 2017-05-16 | 2018-11-22 | Translate Bio, Inc. | Treatment of cystic fibrosis by delivery of codon-optimized mrna encoding cftr |
| MX2020004530A (es) * | 2017-11-18 | 2020-09-18 | Magalhaes Nzola De | Producto y proceso para emplear conjugados de union a antigeno basados en gc7 (n1-guanil-1,7-diaminoheptano) en terapia de cancer. |
| EP3841208A1 (en) | 2018-08-24 | 2021-06-30 | Translate Bio, Inc. | Methods for purification of messenger rna |
| MX2021005969A (es) | 2018-11-21 | 2021-09-14 | Translate Bio Inc | Tratamiento de la fibrosis quística mediante el suministro de arnm que codifica cftr nebulizado. |
| CN114231551B (zh) * | 2021-12-24 | 2023-09-29 | 云南大学 | 蛋白在促进昆虫淋巴细胞凋亡和/或防治害虫中的应用 |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CZ255397A3 (cs) | 1995-02-13 | 1998-02-18 | Novartis Ag | Mutantní proteiny, způsob jejich přípravy, farmaceutické prostředky, které je obsahují, a jejich použití |
| EP1459747A3 (en) * | 1996-09-13 | 2004-12-15 | University Of Florida Research Foundation, Inc. | Method of inhibiting biosynthesis of Elf5A |
| EP1002079A2 (en) | 1997-06-30 | 2000-05-24 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Novel inhibitor of cellular proliferation |
| US6506559B1 (en) * | 1997-12-23 | 2003-01-14 | Carnegie Institute Of Washington | Genetic inhibition by double-stranded RNA |
| US7358418B2 (en) | 1999-07-06 | 2008-04-15 | Senesco Technologies, Inc. | Isoforms of eIF-5A: senescence-induced eLF5A; wounding-induced eIF-4A; growth eIF-5A; and DHS |
| EP1200468A1 (en) | 1999-08-06 | 2002-05-02 | PHARMACIA & UPJOHN COMPANY | CRYSTALLIZATION AND STRUCTURE DETERMINATION OF i STAPHYLOCOCCUS AUREUS /i ELONGATION FACTOR P |
| EP1309726B2 (en) * | 2000-03-30 | 2018-10-03 | Whitehead Institute For Biomedical Research | Rna sequence-specific mediators of rna interference |
| US20040259247A1 (en) * | 2000-12-01 | 2004-12-23 | Thomas Tuschl | Rna interference mediating small rna molecules |
| US7166467B2 (en) * | 2001-07-23 | 2007-01-23 | Senesco Technologies, Inc. | Nucleic acids, polypeptides, compositions, and methods for modulating apoptosis |
| US7381708B2 (en) * | 2001-07-23 | 2008-06-03 | Sensco Technologies, Inc. | Suppression of eIF5A1 expression by the use of antisense oligonucleotides for the prevention of retinal cell death in the glaucomatous eye |
| US7217517B2 (en) * | 2001-07-23 | 2007-05-15 | Senesco Technologies, Inc. | Nucleic acids, polypeptides, and methods for modulating apoptosis |
| JP2003037457A (ja) * | 2001-07-23 | 2003-02-07 | Niigata Seimitsu Kk | 増幅回路 |
| US7968523B2 (en) * | 2001-07-23 | 2011-06-28 | Senesco Technologies, Inc. | Method for inducing apoptosis using apoptosis-specific EIF5-A |
| WO2003016572A1 (en) * | 2001-08-17 | 2003-02-27 | Eli Lilly And Company | Oligonucleotide therapeutics for treating hepatitis c virus infections |
| EP1572902B1 (en) * | 2002-02-01 | 2014-06-11 | Life Technologies Corporation | HIGH POTENCY siRNAS FOR REDUCING THE EXPRESSION OF TARGET GENES |
| DK2284266T3 (da) * | 2002-11-14 | 2014-01-13 | Thermo Fisher Scient Biosciences Inc | sIRNA-MOLEKYLE MOD TP53 |
| NZ542665A (en) | 2003-03-05 | 2008-05-30 | Senesco Technologies Inc | Use of antisense oligonucleotides or siRNA to suppress expression of eIF-5A1 |
| NZ574973A (en) | 2003-06-06 | 2010-10-29 | Senesco Technologies Inc | Inhibition of apoptosis-specific eIF-5A ("eIF-5A1") with antisense oligonucleotides and siRNAs as anti-inflammatory therapeutics |
-
2004
- 2004-03-05 NZ NZ542665A patent/NZ542665A/en unknown
- 2004-03-05 WO PCT/US2004/006598 patent/WO2004078940A2/en not_active Ceased
- 2004-03-05 AU AU2004217437A patent/AU2004217437B2/en not_active Ceased
- 2004-03-05 CA CA002517974A patent/CA2517974A1/en not_active Abandoned
- 2004-03-05 JP JP2006509126A patent/JP2006520611A/ja active Pending
- 2004-03-05 EP EP04717933A patent/EP1601767B1/en not_active Expired - Lifetime
- 2004-03-05 TW TW093105908A patent/TW200427695A/zh unknown
- 2004-03-05 KR KR1020057015276A patent/KR20050098954A/ko not_active Ceased
-
2005
- 2005-05-23 US US11/134,445 patent/US20100168047A9/en not_active Abandoned
- 2005-11-28 US US11/287,460 patent/US7662796B2/en not_active Expired - Fee Related
-
2009
- 2009-12-17 US US12/640,148 patent/US8242256B2/en not_active Expired - Fee Related
-
2011
- 2011-05-02 US US13/099,171 patent/US8754057B2/en not_active Expired - Fee Related
-
2012
- 2012-08-10 US US13/572,123 patent/US20130066058A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2006520611A5 (enExample) | ||
| US9840707B2 (en) | Modified TGF-beta2 oligonucleotides | |
| CN104857526B (zh) | 治疗眼部疾病的方法 | |
| JP7394815B2 (ja) | ＮＲＡＲＰ遺伝子の発現を阻害するためのｓｉＲＮＡ、並びにそのための方法及び組成物におけるそれらの使用 | |
| US20060031946A1 (en) | Gene therapy with chimeric oligonucleotides delivered by a method comprising a step of iontophoresis | |
| EP3060663A2 (en) | Sirna and their use in methods and compositions for inhibiting the expression of the orai1 gene | |
| US9951338B2 (en) | siRNA and their use in methods and compositions for inhibiting the expression of the PDK1 gene | |
| WO2017042239A1 (en) | siRNA and their use in methods and compositions for inhibiting the expression of the CHI3L1 gene | |
| HK1257658B (en) | Sirna and their use in methods and compositions for inhibiting the expression of the nrarp gene |